Acadia Pharma (ACAD) Reports Positive Top-line Results from the Pivotal Phase 3 Lavender Trial of Trofinetide in Rett Syndrome
Go back to Acadia Pharma (ACAD) Reports Positive Top-line Results from the Pivotal Phase 3 Lavender Trial of Trofinetide in Rett Syndrome| Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) | Delayed: 22.09 +0.47 (2.17%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $21.62 | 52 Week High | $42.49 | |||
| Open | $21.64 | 52 Week Low | $16.64 | |||
| Day High | $22.46 | P/E | N/A | |||
| Day Low | $21.59 | EPS | $-0.42 | |||
| Volume | 1,904,396 | |||||
